| Product Unit Size | Cost | Quantity | Stock |
|---|
AZD-4547 is an inhibitor of FGFR that is somewhat selective for FGFR2 over FGFR1 and FGFR3; it exhibits anticancer chemotherapeutic activities. This compound is currently in clinical trials as a potential treatment for breast cancer. In breast cancer cells, AZD-4547 induces apoptosis and inhibits cellular proliferation, invasion and migration. In vivo, this compound inhibits tumor growth and metastasis.
| Cas No. | 1035270-39-3 |
|---|---|
| Purity | ≥98% |
| Formula | C26H33N5O3 |
| Formula Wt. | 463.57 |
| IUPAC Name | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide |
| Synonym | AZD-4547 |
| Solubility | DMSO 92 mg/mL (198.45 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Liu L, Ye TH, Han YP, et al. Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell Physiol Biochem. 2014;33(3):633-45. PMID: 24642893.
Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012 Dec 15;18(24):6658-67. Erratum in: Clin Cancer Res. 2013 Jul 1;19(13):3714. Schöttle, Jakob [added]. PMID: 23082000.
Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56. PMID: 22369928.